Antroquinonol

Drug Profile

Antroquinonol

Alternative Names: Hocena

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Golden Biotechnology Corporation
  • Developer China Sky One Medical; Golden Biotechnology Corporation; Queensland University of Technology
  • Class Alkenes; Antineoplastics; Cyclohexenes; Ketones
  • Mechanism of Action Epidermal growth factor receptor modulators; Mitogen-activated protein kinase modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Acute myeloid leukaemia; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Hyperlipidaemia; Non-small cell lung cancer; Pancreatic cancer
  • Preclinical Alzheimer's disease
  • No development reported Cancer

Most Recent Events

  • 19 May 2017 Golden Biotechnology Corporation plans a clinical trial for Pancreatic cancer (First-line therapy, adjunctive therapy) in USA
  • 18 Jan 2017 Antroquinonol receives Orphan Drug status for Pancreatic cancer in European Union
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top